A randomized phase II study of docetaxel or vinorelbine in combination with cisplatin against inoperable, chemo-naïve non-small-cell lung cancer in Taiwan-Reference-Cited by-同舟云学术

A randomized phase II study of docetaxel or vinorelbine in combination with cisplatin against inoperable, chemo-naïve non-small-cell lung cancer in Taiwan

Published:2007-06 Issue:3 Volume:56 Page:363-369
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Chen Yuh-Min,Perng Reury-Perng,Shih Jen-Fu,Tsai Chun-Ming,Whang-Peng Jacqueline

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference22 articles.

1. Global cancer statistics;Parkin;Can Cancer J Clin,2005

2. American society of clinical oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003;Pfister;J Clin Oncol,2004

3. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: results of a European multicenter trial including 612 patients;Le Chevalier;J Clin Oncol,1994

4. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer;Schiller;New Engl J Med,2002

5. Third-generation chemotherapy regimens (3GR) improve survival over second-generation regimens (2GR) in stage IIIB/IV non-small cell lung cancer (NSCLC): a meta-analysis of the published literature;Baggstrom;Proc Am Soc Clin Oncol,2002

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real world results of locally advanced and metastatic lung cancer patients treated with platinum doublet chemotherapy in first line: Moroccan cohort;Translational Oncology;2024-09

2. The best regimens for chemo-naïve incurable non-squamous non- small cell lung cancer with a programmed death-ligand 1, tumor proportion score 1–49%: a network meta-analysis;Translational Lung Cancer Research;2021-08

Changes and Influential Factors of Chemotherapy Usage for Non-Small Cell Lung Cancer Patients in China: A Multicenter 10-Year (2005–2014) Retrospective Study

;Cancer Management and Research;2020-07

4. S‐1 plus cisplatin as first‐line treatment of patients with advanced non‐small cell lung cancer in Taiwan;Asia-Pacific Journal of Clinical Oncology;2020-04

5. A Randomized Multicenter Phase III Study of Single Administration of Mecapegfilgrastim (HHPG-19K), a Pegfilgrastim Biosimilar, for Prophylaxis of Chemotherapy-Induced Neutropenia in Patients With Advanced Non–Small-Cell Lung Cancer (NSCLC);Clinical Lung Cancer;2016-03